Altimmune, Inc. Cash Flow Statement
ALT|10 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Altimmune, Inc. used $68M in operating cash flow and negative free cash flow of $68M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$88.1M | -$88.4M | -$84.7M | -$97.1M | -$49.0M | -$20.5M | -$39.2M | -$46.4M | -$11.1M | -$34.8M |
| Depreciation & Amortization | - | $477.0K | $493.0K | $400.0K | $428.9K | $387.3K | $218.7K | $83.8K | $63.1K | $1.0M |
| Operating Cash Flow | -$67.5M | -$75.8M | -$62.6M | -$78.2M | -$34.3M | -$9.6M | -$9.4M | -$20.2M | -$6.4M | -$14.9M |
| Capital Expenditures | $11.0K | $47.0K | $126.0K | $12.1M | $204.0K | $1.2K | $975.4K | $112.4K | $125.0K | $374.6K |
| Free Cash Flow | -$67.5M | -$75.9M | -$62.7M | -$90.4M | -$34.5M | -$9.6M | -$10.4M | -$20.3M | -$6.5M | -$15.2M |
| FCF Margin | -164746.3% | -17806.8% | 92223.5% | -2048.9% | -421.6% | -165.5% | -100.3% | -189.3% | -200.2% | -72.6% |